We also need to highlight that the co-occurrence of autoimmune responses in cancer patients or the presentation of associated autoimmune diseases and cancer [107] may putatively suggest the double-utility of p53 reactivation as therapeutic goal. Here, TP53 is linked to autoimmune disease.